Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

Neuro-Oncology

Volumn 9, Issue 1, 2007, Pages 70-74

  Badruddoja, Michael A ^a,e   Penne, Kara ^a   Desjardins, Annick ^a   Reardon, David A ^a   Rich, Jeremy N ^b   Quinn, Jennifer A ^b   Sathornsumetee, Sith ^a   Friedman, Allan H ^a   Bigner, Darell D ^c   Herndon II, James E ^c   Cahill, Ann ^d   Friedman, Henry S ^a   Vredenburgh, James J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Vion Pharmaceuticals Incorporated   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cloretazine; Glioblastoma multiforme

Indexed keywords

1,2 BIS(METHYLSULFONYL) 1 (2 CHLOROETHYL)HYDRAZINE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALKYLATING AGENT; ANTICONVULSIVE AGENT; CARMUSTINE; CLORETAZINE; CORTICOSTEROID; DRUG METABOLITE; GUANINE; HEMOPOIETIC GROWTH FACTOR; LOMUSTINE; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 1,2 BIS(METHYLSULFONYL) 1 (2 CHLOROETHYL) 2 ((2 METHYLAMINO)CARBONYL)HYDRAZINE; 1,2-BIS(METHYLSULFONYL)-1-(2-CHLOROETHYL)-2-((2-METHYLAMINO)CARBONYL)HYDRAZINE; HYDRAZINE DERIVATIVE; SULFONAMIDE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; ADULT; AGED; BRAIN TUMOR; DISEASE COURSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; HYDRAZINES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SULFONAMIDES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34047230537     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-022     Document Type: Article

References (15)

1. Dropcho, E. (2001) Novel chemotherapeutic approaches to brain tumors. Hematol. Oncol. Clin. North Am. 15, 1027-1052.
2. Eagan, R.T., and Scott, M. (1983) Evaluation of prognostic factors in chemotherapy of recurrent brain tumors, J. Clin. Oncol. 1, 38-44.
3. Fine, H.A. (1994) The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. 20, 111-120.
4. Garrett, M.J., Hughes, H.J., and Freedman, L.S. (1978) A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin. Oncol. 4, 71-76.
5. Levin, V.A., Wara, W.M., Davis, R.L., Vestnys, P., Resser, K.J., Yatsko, K., Nutik, S., Gutin, P.H., and Wilson, C.B. (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg. 63, 218-223.
6. Macdonald, D.R., Cascino, T.L., Schold Jr., S.C., and Cairncross, J.C. (1990) Response criteria for phase Il studies of supratentorial malignant glioma. Clin. Oncol. 8, 1277-1280.
7. 6-alkylguanine-DNA alkyltransferase (ACT) by electrophilic species generated during the decomposition of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamion) carbonyl]hydrazine (VNP40101M). 94th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, July 11-14.
8. Penketh, P.C., Shyam, K., and Sartorelli, A.C. (2000) Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem. Pharmacol. 59, 283-291.
9. Rice, K.P., Penketh, P.G., Shyam, K., and Sartorelli, A.C. (2005) Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU. Biochem. Pharmacol. 69, 1463-1472.
10. Shapiro, W.R. (1986) Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin. Oncol. 13, 38-45.
11. Solero, C.L., Monfardini, S., Brambilla, C., Vaghi, A., Valagussa, P., Morello, C., and Bonadonna, G. (1979) Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin. Trials 2, 43-48.
12. Stupp, R., Mason, W., Van Den Bent, M., Weller, M., Fisher, B., Taphoorn, M., Brandes, A., Cairncross, C., Lacombe, D., and Mirimanoff, R. (2004) Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM): Conclusive results of a randomized phase III trial by the EORTC brain & RT groups and NCIC clinical trials group. 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 5-8.
13. Walker, M.D., Green, S.B., Byar, O.P., Alexander Jr., E., Batzdorf, U., Brooks, W.H., Hunt, W.E., MacCarty, C.S., Mahaley Jr., M.S., Mealey Jr., J., Owens, C., Ransohoff, J., II, Robertson, J.T., Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323-1329.
14. 6- alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 5, 121-124.
15. Yung, W.K., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R. C., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588-593.